Yet again one of our resident trolls displaying his clear ASX disclosure ignorance, poor attention to detail and inability to read, in an effort to spread FUD. Two upvotes though, so not alone in his defence.
EVERY Appendix 4C, by every ASX listed company, has as standard 8.5 entry, an estimated quarters of funding available by dividing 8.4, Total available funding (item 8.2 + item 8.3; cash and cash equivalents at quarter end plus unused finance facilities available at quarter end) by 8.1, qtrly net cash from / (used in) operating activities (in the period).
What appalling basic understanding of lumpy cash flows that the trolls think it that simple.
The company clearly guided on its forthcoming cash use in several areas:
"The Company currently expects its cash runway to extend into the 2025-26 financial year. In accordance with ASX rules, the “Estimated quarters of funding available” reported in item 8.5 of the Appendix 4C is calculated by dividing the cash at the end of the quarter by the net operating cash outflows in the previous quarter, and the result of this calculation is 12.6 quarters of funding available. However, as the net operating cash outflows in the previous quarter were not representative of forecasted expenditure in the forthcoming two financial years, this is not consistent with the Company’s expectations. "
Perhaps its just my poor vocabular; ignorance and arrogance descriptions we understand, but I feel there needs to be a word to describe people who sternly express their so clearly ignorantly formed and misguided opinions with disdainful arrogance. The company's cash flows were quite clearly guided along with results timelines for context:
"Solid cash balance of A$11.2m at end of quarter, with forecast cash runway into H2 2025"
"the Company’s expectation remains that [GvHD] enrolment will be completed by the end of calendar year 2024, with primary results available by H2 2025."
"Phase 1 clinical trial in diabetic foot ulcer (DFU): initial results expected Q1 2024" (fuller results 1H 2024)
"During the quarter, [Sculptor] trial recruitment was completed, with a total of 321 participants enrolled. In accordance with the study protocol, patients will be followed up for two years, to allow sufficient time for a potential disease modifying effect to be assessed. As such, the Company anticipates that the last participant visit will occur around November 2025, with results expected in the first half of 2026."
15 cents to 21.5 cents back to 16 cents in 5 days. Doesn't take much to persuade and dissuade people in this stock....
Expand
